Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GWP42006 add-on therapy in focal seizures (PK, efficacy and safety)
2014-002594-11Phase 2Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in Focal Onset Epilepsy (4 arms), sponsored by GW Pharmaceuticals. Primary endpoints: Part A pharmacokinetic parameters of GWP42006 and metabolites and Part B efficacy endpoints. Started Sep 2014; status: completed.
02
Drugs
cannabidiol
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on 2014-002594-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002594-11.